http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
Gelesis to Report Third Quarter 2022 Financial Results on November 14, 2022
-
Data Presented at Obesity Week Demonstrate that Gelesis Investigational Clinical-Stage Oral Superabsorbent Hydrogel Gel-B Preferentially Enhances the Growth of Akkermansia muciniphila in Preclinical M
-
Dr. Frank Greenway to Present Data from the LIGHT-UP Study with Gelesis’ Oral Hydrogel Treatment GS200 at Obesity Week
-
Gelesis to Participate in the Jefferies Virtual Fitness & Wellness Summit
-
Clinical Data from the LIGHT-UP Study Presented at the International Congress of Endocrinology Suggests New Gelesis Oral Hydrogel May Improve Insulin Sensitivity and Favorably Impact Metabolic Syndrom
-
PureTech Health plc – Half-Year Report
-
Gelesis to Participate in Fireside Chat with IPO Edge Today at 2:00 PM ET
-
Gelesis Reports Second Quarter 2022 Results
-
Gelesis to Report Second Quarter 2022 Financial Results on August 15, 2022
-
Gelesis Holdings (GLS) Announces Additional $15 Million Pre-Order for Plenity
-
Gelesis Announces Additional $15 Million Pre-Order for Plenity®, Bringing Total Pre-Paid Orders from Ro for Plenity to $55 Million
-
Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study
-
Microbiota Transplantation Demonstrates How Gut Bacteria Contributes to Weight Loss and Beneficial Metabolic Effects with Gelesis’ Proprietary Hydrogel
-
Gelesis to Participate in Upcoming Investor Conferences
-
Gelesis Reports First Quarter 2022 Results
-
Gelesis to Report First Quarter 2022 Financial Results on May 12, 2022
-
PureTech Founded Entity Gelesis Announces Clinical Data Demonstrating Weight Loss with GS200 in Adults with Prediabetes and Type 2 Diabetes Presented at the European Congress on Obesity 2022
-
Gelesis Holdings (GLS) Reports Data Demonstrating Weight Loss With GS200 in Adults With Prediabetes and Type 2 Diabetes
-
Clinical Data Presented at the European Congress on Obesity 2022 Demonstrates Weight Loss With GS200 in Adults With Prediabetes and Type 2 Diabetes
-
PureTech Founded Entity Gelesis Announces its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Hea
-
Gelesis Holdings (GLS) Reports its Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia
-
Gelesis’ Proprietary Superabsorbent Hydrogel Induced Beneficial Changes to the Gut Microbiota and Expanded Akkermansia, a Bacterial Species Associated with Gut Health and Weight Loss, in New Study
-
Gelesis® Reports Fiscal Year 2021 Results and Fiscal Year 2022 Financial Outlook
-
Gelesis to Report Full Year 2021 Financial Results on March 24, 2022
-
PureTech Health's (PRTC) Gelesis Holdings (GLS) Reports Record Preliminary National Launch Results for Plenity
-
PureTech Founded Entity Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online Traffic
-
Gelesis® Releases Preliminary National Launch Results for Plenity®: Record-Breaking Levels of Prescriptions and Online Traffic
-
PureTech Founded Entity Gelesis to Launch Plenity® National Media Campaign That Challenges Restrictive Dieting Norms
-
Plenity® National Media Campaign Kicking Off Today Challenges Restrictive Dieting Norms
-
PureTech Founded Entity Akili Interactive, a Leader in Digital Medicine, to Become Publicly Traded Through Combination with Social Capital Suvretta Holdings Corp. I
-
Gelesis®, the Maker of Plenity® for Weight Management, Will Debut as a Publicly Traded Company Following the Closing of Its Business Combination with Capstar
-
Gelesis to Become Publicly Traded Company via Merger with Capstar Special Purpose Acquisition Corp. (CPSR)

